About the 3rd Annual IOBDLI Forum

Taking place on the first day of ASCO, the 3rd Annual Immuno-Oncology: BD&L and Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering, funding and investment. We expect around 250 delegates and about 30 presentations by listed and private biotechnology companies seeking licensing & investment. Numerous networking opportunities available via an online one-to-one meeting system with dedicated meeting facilities to make the event more transactional.
Plenary Sessions will include:
​
  • Industry Roundtable: “The Changing Landscape of Regulation, Reimbursement & Pricing Under the New Administration"
  • Current Trends in Pharma-Biotech Deal Making
  • New Approaches to IO & Combination Therapies
  • Latest Perspectives on Cell & Gene Therapies
  • Technology & Innovation
  • New Session: China-US DealMaking with overview by Helen Chen, Managing Director and Head of China Life Sciences, L.E.K. Consulting
  • Investor Roundtable
​Confirmed Keynotes Include:​
​
  • “Oncology within the Context of the Changing Reimbursement Landscape” by Roger Longman, CEO, Real Endpoints
  • ​​“Perspectives on Cell Therapies” by Samuele Butera, Global Cell & Gene Therapies Business Leader, Novartis Oncology
Confirmed Speakers Include:​​​
  • Aaron Foster, Vice President of Product Discovery, Bellicum Pharmaceuticals, Inc. 
  • Axel Hoos, SVP, TA Head, Oncology R&D, GSK
  • Bard Geesaman, Managing Director, MPM Capital
  • Bibhash Mukhopadhyay, Principal, New Enterprise Associates
  • Boris Peaker, Managing Partner, Biotechnology Equity Research, Cowen and Company
  • Brad Loncar, CEO, Loncar Investments
  • Chris DeRespino, Director, Business Development, Amgen, Inc.
  • David Malek, Chief Business Officer, BioLineRx Ltd.
  • Debra Bowes, EVP, Business and Strategic Development, MaxCyte, Inc.
  • Ferran Prat, VP, Strategic Industry Ventures, MD Anderson Cancer Center
  • Francis Kern, Senior Director of External Scientific Affairs, Daiichi Sankyo
  • Gary Sclar, Vice President, Dana-Farber Innovations, Dana-Farber Cancer Institute
  • Gregory Frost, CEO and Chairman, F1BioVentures
  • Gregory Naeve, Head External R&D Innovation, ImmunoOncology & Rinat Labs, San Francisco, Pfizer, Inc.
  • Guillaume Vignon, Head of Immuno-Oncology Licensing & Business Development , EMD Serono, Inc.
  • Helen Chen, Managing Director and Head of China Life Sciences, L.E.K. Consulting Limited
  • Helen Tayton-Martin, Chief Business Officer, Adaptimmune Therapeutics
  • Hongbo Lu, Partner, Lilly Asian Venture
  • Howard Fingert, Senior Medical Director for Clinical Intelligence, Takeda Pharmaceuticals
  • Ian Woo, Managing Director, Healthcare Banking, Lazard
  • James Mulé, Associate Center Director for Translational Research, Moffitt Cancer Center
  • Ji Li, Global Head of Business Development, BeiGene
  • John Beadle, CEO, PsiOxus Therapeutics Ltd.
  • Joseph Sum, Director of Research, EcoR1 Capital, LLC
  • Juergen Gamer, VP Business Development, Apogenix AG
  • Julie Locklear, Vice President & Head Health Economics & Outcomes Research, EMD Serono, Inc.
  • Kuldeep Neote, Senior Director, New Ventures, J&J Innovation Centre-Boston
  • Lee Greenberger, SVP and CSO, The Leukemia & Lymphoma Society
  • Lindy  Durrant , CSO, Scancell Limited
  • Lisa Decker, Executive Director, Business Development, Nektar Therapeutics
  • Loic Vincent, Head, Immunology Partnerships, Takeda Pharmaceuticals
  • Michael Margolis, Co-Head of Healthcare Investment Banking, Oppenheimer & Co., Inc.
  • Mike Rice, Principal, Defined Health, a Cello Health Business
  • Patrick Tricoli, CEO , Nanobiotix Corp.
  • Paul Rennert, President & CSO, Aleta Biotherapeutics
  • Peter Emtage, Chief Scientific Officer, Cell Design Labs
  • Peter Sandor, Vice President, Oncology Therapeutic Area Head for Marketing Strategy, Astellas Pharma US, Inc.
  • Peter Thompson, Private Equity Partner, OrbiMed Advisors LLC
  • Rahul  Jasuja, CEO & Board Member, Pelican Therapeutics
  • Rena Conti, Assistant Professor Hematology/Oncology, Department of Pediatrics, The University of Chicago
  • Roger Longman, CEO, Real Endpoints
  • Sachin Kamal-Bahl, Vice President and Head, Innovation Center, Patient & Health Impact, Pfizer, Inc.
  • Samuele Butera, Global Cell & Gene Therapies Business Leader, Novartis Oncology
  • Stephen Sands, BD&L Director Oncology/Immunology, F. Hoffmann-La Roche Ltd.
  • Thilo Schroeder, Partner, Nextech Invest Ltd.
  • Timothy Herpin, VP, Head of Transactions (UK), Business Development, AstraZeneca
  • Walter Lau, Managing Partner, Cenova Venture
  • Weimin Tang, Executive Director, Business Development, Jiangsu Hengrui Medicine Co.
  • Yuwen Liu, Founding Partner, BoHe Angel Fund

Presenting Opportunities:

Presenting at the forum offers excellent opportunities to showcase activities and highlight investment and partnership opportunities. Biotech companies will be able to communicate investment and licensing opportunities. These are for both public and private companies. The audience is comprised of financial and industry investors. These are streamed 10 or 20 minute presentations, also available as live-stream or recorded and edited.

Sachs forums are recognised as the leading international stage for those interested in investing in the biotech and life science industry and are highly transactional. They draw together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharmas. The Chicago forum provides the additional interaction with the academic/scientific and patient advocacy communities.

Sponsorship and Exhibition:

Sachs Associates has developed an extensive knowledge of the key individuals operating within the European and global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at the forefront of the industry and provides a powerful tool by which to increase the position of your company in this market.
​
Raise your company’s profile directly with your potential clients. All of our sponsorship packages are tailor made to each client, allowing your organisation to gain the most out of attending our industry driven events.

To learn more about presenting, exhibition or sponsorship opportunities, please contact: Silvia Kar on +44 203 463 4890 or by email: Silvia.
Supporters
Pharma Licensing Groups Attending:
​Financial
Advisory/Investors 
Attending in 2016:
Alpha Bronze
Altius Strategy Consulting
Amorchem
Aquilo Capital Management
Aurgalys
Biotech Alliances International, Inc.
BTIG, LLC
Calamos Investments
Cantor Fitzgerald
Chardan Capital Markets, LLC
Cowen and Company
Dawson James Securities, Inc.
Deca Ventures
EcoR1 Capital, LLC
Edison Group
Enso Ventures
F1BioVentures
FBR & Co.
GreenPeptide Co., Ltd.
H.C. Wainwright & Co., LLC
Healthy Assets
Jefferies, LLC
JP Morgan
Katan Family Office

View All Here